Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design
Identifieur interne : 000C17 ( PascalFrancis/Corpus ); précédent : 000C16; suivant : 000C18Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design
Auteurs : Lisa S. Friedman ; Jennifer M. Farmer ; Susan Perlman ; George Wilmot ; Christopher M. Gomez ; Khalaf O. Bushara ; Katherine D. Mathews ; S. H. Subramony ; Tetsuo Ashizawa ; Laura J. Balcer ; Robert B. Wilson ; David R. LynchSource :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner-rated functional disability scales, self-reported activities of daily living and performance measures such as the timed 25-foot walk, 9-hole pegboard test, PATA speech test, and low-contrast letter acuity vision charts. This study examines the rate of disease progression over one and two years in a cohort of 236 Friedreich ataxia patients using these scales and performance measure composites. The Friedreich Ataxia Rating Scale and performance-measure composites captured disease progression, with a greater sensitivity to change over 2 years than over 1 year. The measures differed in their sensitivity to change and in possible bias. These results help to establish norms for progression in FRDA that can be useful in measuring the long-term success of therapeutic agents and defining sample-size calculations for double-blind clinical trials.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 10-0178204 INIST |
---|---|
ET : | Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design |
AU : | FRIEDMAN (Lisa S.); FARMER (Jennifer M.); PERLMAN (Susan); WILMOT (George); GOMEZ (Christopher M.); BUSHARA (Khalaf O.); MATHEWS (Katherine D.); SUBRAMONY (S. H.); ASHIZAWA (Tetsuo); BALCER (Laura J.); WILSON (Robert B.); LYNCH (David R.) |
AF : | Department of Neurology, School of Medicine, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 10 aut., 12 aut.); Department of Pediatrics, School of Medicine, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 12 aut.); Children's Hospital of Philadelphia/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 12 aut.); Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles/Los Angeles, California/Etats-Unis (3 aut.); Department of Neurology, Emory University/Atlanta, Georgia/Etats-Unis (4 aut.); Department of Neurology, University of Minnesota/Minneapolis, Minnesota/Etats-Unis (5 aut., 6 aut.); Department of Neurology, University of Chicago/Chicago, Illinois/Etats-Unis (5 aut.); Departments of Neurology and Pediatrics, University of Iowa/Iowa City, Iowa/Etats-Unis (7 aut.); Department of Neurology, University of Texas Medical Branch/Galveston, Texas/Etats-Unis (8 aut., 9 aut.); Department of Neurology, University of Mississippi/Jackson, Mississippi/Etats-Unis (8 aut.); Department of Neurology, University of Florida/Gainesville, Florida/Etats-Unis (9 aut.); Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (11 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 4; Pp. 426-432; Bibl. 17 ref. |
LA : | Anglais |
EA : | Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner-rated functional disability scales, self-reported activities of daily living and performance measures such as the timed 25-foot walk, 9-hole pegboard test, PATA speech test, and low-contrast letter acuity vision charts. This study examines the rate of disease progression over one and two years in a cohort of 236 Friedreich ataxia patients using these scales and performance measure composites. The Friedreich Ataxia Rating Scale and performance-measure composites captured disease progression, with a greater sensitivity to change over 2 years than over 1 year. The measures differed in their sensitivity to change and in possible bias. These results help to establish norms for progression in FRDA that can be useful in measuring the long-term success of therapeutic agents and defining sample-size calculations for double-blind clinical trials. |
CC : | 002B17; 002B17F |
FD : | Hérédodégénérescence spinocérébelleuse de Friedreich; Ataxie; Cytopathie mitochondriale; Pathologie du système nerveux; Essai clinique; Neurologie; Trinucléotide |
FG : | Pathologie de l'encéphale; Maladie dégénérative; Maladie héréditaire; Pathologie de la moelle épinière; Pathologie du système nerveux central; Trouble neurologique; Enzymopathie; Maladie métabolique |
ED : | Friedreich ataxia; Ataxia; Mitochondrial disorder; Nervous system diseases; Clinical trial; Neurology; Trinucleotide |
EG : | Cerebral disorder; Degenerative disease; Genetic disease; Spinal cord disease; Central nervous system disease; Neurological disorder; Enzymopathy; Metabolic diseases |
SD : | Heredodegeneración espinocerebelosa Friedreich; Ataxia; Citopatía mitocondrial; Sistema nervioso patología; Ensayo clínico; Neurología; Trinucleótido |
LO : | INIST-20953.354000181523490050 |
ID : | 10-0178204 |
Links to Exploration step
Pascal:10-0178204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design</title>
<author><name sortKey="Friedman, Lisa S" sort="Friedman, Lisa S" uniqKey="Friedman L" first="Lisa S." last="Friedman">Lisa S. Friedman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Farmer, Jennifer M" sort="Farmer, Jennifer M" uniqKey="Farmer J" first="Jennifer M." last="Farmer">Jennifer M. Farmer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perlman, Susan" sort="Perlman, Susan" uniqKey="Perlman S" first="Susan" last="Perlman">Susan Perlman</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilmot, George" sort="Wilmot, George" uniqKey="Wilmot G" first="George" last="Wilmot">George Wilmot</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gomez, Christopher M" sort="Gomez, Christopher M" uniqKey="Gomez C" first="Christopher M." last="Gomez">Christopher M. Gomez</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, University of Chicago</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bushara, Khalaf O" sort="Bushara, Khalaf O" uniqKey="Bushara K" first="Khalaf O." last="Bushara">Khalaf O. Bushara</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mathews, Katherine D" sort="Mathews, Katherine D" uniqKey="Mathews K" first="Katherine D." last="Mathews">Katherine D. Mathews</name>
<affiliation><inist:fA14 i1="08"><s1>Departments of Neurology and Pediatrics, University of Iowa</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Subramony, S H" sort="Subramony, S H" uniqKey="Subramony S" first="S. H." last="Subramony">S. H. Subramony</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, University of Texas Medical Branch</s1>
<s2>Galveston, Texas</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurology, University of Mississippi</s1>
<s2>Jackson, Mississippi</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ashizawa, Tetsuo" sort="Ashizawa, Tetsuo" uniqKey="Ashizawa T" first="Tetsuo" last="Ashizawa">Tetsuo Ashizawa</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, University of Texas Medical Branch</s1>
<s2>Galveston, Texas</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Balcer, Laura J" sort="Balcer, Laura J" uniqKey="Balcer L" first="Laura J." last="Balcer">Laura J. Balcer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilson, Robert B" sort="Wilson, Robert B" uniqKey="Wilson R" first="Robert B." last="Wilson">Robert B. Wilson</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lynch, David R" sort="Lynch, David R" uniqKey="Lynch D" first="David R." last="Lynch">David R. Lynch</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0178204</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0178204 INIST</idno>
<idno type="RBID">Pascal:10-0178204</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design</title>
<author><name sortKey="Friedman, Lisa S" sort="Friedman, Lisa S" uniqKey="Friedman L" first="Lisa S." last="Friedman">Lisa S. Friedman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Farmer, Jennifer M" sort="Farmer, Jennifer M" uniqKey="Farmer J" first="Jennifer M." last="Farmer">Jennifer M. Farmer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perlman, Susan" sort="Perlman, Susan" uniqKey="Perlman S" first="Susan" last="Perlman">Susan Perlman</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilmot, George" sort="Wilmot, George" uniqKey="Wilmot G" first="George" last="Wilmot">George Wilmot</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gomez, Christopher M" sort="Gomez, Christopher M" uniqKey="Gomez C" first="Christopher M." last="Gomez">Christopher M. Gomez</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, University of Chicago</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bushara, Khalaf O" sort="Bushara, Khalaf O" uniqKey="Bushara K" first="Khalaf O." last="Bushara">Khalaf O. Bushara</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mathews, Katherine D" sort="Mathews, Katherine D" uniqKey="Mathews K" first="Katherine D." last="Mathews">Katherine D. Mathews</name>
<affiliation><inist:fA14 i1="08"><s1>Departments of Neurology and Pediatrics, University of Iowa</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Subramony, S H" sort="Subramony, S H" uniqKey="Subramony S" first="S. H." last="Subramony">S. H. Subramony</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, University of Texas Medical Branch</s1>
<s2>Galveston, Texas</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="10"><s1>Department of Neurology, University of Mississippi</s1>
<s2>Jackson, Mississippi</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ashizawa, Tetsuo" sort="Ashizawa, Tetsuo" uniqKey="Ashizawa T" first="Tetsuo" last="Ashizawa">Tetsuo Ashizawa</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, University of Texas Medical Branch</s1>
<s2>Galveston, Texas</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Balcer, Laura J" sort="Balcer, Laura J" uniqKey="Balcer L" first="Laura J." last="Balcer">Laura J. Balcer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilson, Robert B" sort="Wilson, Robert B" uniqKey="Wilson R" first="Robert B." last="Wilson">Robert B. Wilson</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lynch, David R" sort="Lynch, David R" uniqKey="Lynch D" first="David R." last="Lynch">David R. Lynch</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ataxia</term>
<term>Clinical trial</term>
<term>Friedreich ataxia</term>
<term>Mitochondrial disorder</term>
<term>Nervous system diseases</term>
<term>Neurology</term>
<term>Trinucleotide</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hérédodégénérescence spinocérébelleuse de Friedreich</term>
<term>Ataxie</term>
<term>Cytopathie mitochondriale</term>
<term>Pathologie du système nerveux</term>
<term>Essai clinique</term>
<term>Neurologie</term>
<term>Trinucléotide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner-rated functional disability scales, self-reported activities of daily living and performance measures such as the timed 25-foot walk, 9-hole pegboard test, PATA speech test, and low-contrast letter acuity vision charts. This study examines the rate of disease progression over one and two years in a cohort of 236 Friedreich ataxia patients using these scales and performance measure composites. The Friedreich Ataxia Rating Scale and performance-measure composites captured disease progression, with a greater sensitivity to change over 2 years than over 1 year. The measures differed in their sensitivity to change and in possible bias. These results help to establish norms for progression in FRDA that can be useful in measuring the long-term success of therapeutic agents and defining sample-size calculations for double-blind clinical trials.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FRIEDMAN (Lisa S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FARMER (Jennifer M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PERLMAN (Susan)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WILMOT (George)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GOMEZ (Christopher M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BUSHARA (Khalaf O.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MATHEWS (Katherine D.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SUBRAMONY (S. H.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>ASHIZAWA (Tetsuo)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>BALCER (Laura J.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>WILSON (Robert B.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LYNCH (David R.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pediatrics, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Children's Hospital of Philadelphia</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, University of Chicago</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Departments of Neurology and Pediatrics, University of Iowa</s1>
<s2>Iowa City, Iowa</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurology, University of Texas Medical Branch</s1>
<s2>Galveston, Texas</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Neurology, University of Mississippi</s1>
<s2>Jackson, Mississippi</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neurology, University of Florida</s1>
<s2>Gainesville, Florida</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>426-432</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000181523490050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0178204</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner-rated functional disability scales, self-reported activities of daily living and performance measures such as the timed 25-foot walk, 9-hole pegboard test, PATA speech test, and low-contrast letter acuity vision charts. This study examines the rate of disease progression over one and two years in a cohort of 236 Friedreich ataxia patients using these scales and performance measure composites. The Friedreich Ataxia Rating Scale and performance-measure composites captured disease progression, with a greater sensitivity to change over 2 years than over 1 year. The measures differed in their sensitivity to change and in possible bias. These results help to establish norms for progression in FRDA that can be useful in measuring the long-term success of therapeutic agents and defining sample-size calculations for double-blind clinical trials.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hérédodégénérescence spinocérébelleuse de Friedreich</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Friedreich ataxia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Heredodegeneración espinocerebelosa Friedreich</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ataxie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Ataxia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ataxia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Cytopathie mitochondriale</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mitochondrial disorder</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Citopatía mitocondrial</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Neurologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Neurology</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Neurología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Trinucléotide</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Trinucleotide</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Trinucleótido</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de la moelle épinière</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Spinal cord disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Médula espinal patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Enzymopathie</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Enzymopathy</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enzimopatía</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>45</s5>
</fC07>
<fN21><s1>116</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0178204 INIST</NO>
<ET>Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design</ET>
<AU>FRIEDMAN (Lisa S.); FARMER (Jennifer M.); PERLMAN (Susan); WILMOT (George); GOMEZ (Christopher M.); BUSHARA (Khalaf O.); MATHEWS (Katherine D.); SUBRAMONY (S. H.); ASHIZAWA (Tetsuo); BALCER (Laura J.); WILSON (Robert B.); LYNCH (David R.)</AU>
<AF>Department of Neurology, School of Medicine, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 10 aut., 12 aut.); Department of Pediatrics, School of Medicine, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 12 aut.); Children's Hospital of Philadelphia/Philadelphia, Pennsylvania/Etats-Unis (1 aut., 2 aut., 12 aut.); Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles/Los Angeles, California/Etats-Unis (3 aut.); Department of Neurology, Emory University/Atlanta, Georgia/Etats-Unis (4 aut.); Department of Neurology, University of Minnesota/Minneapolis, Minnesota/Etats-Unis (5 aut., 6 aut.); Department of Neurology, University of Chicago/Chicago, Illinois/Etats-Unis (5 aut.); Departments of Neurology and Pediatrics, University of Iowa/Iowa City, Iowa/Etats-Unis (7 aut.); Department of Neurology, University of Texas Medical Branch/Galveston, Texas/Etats-Unis (8 aut., 9 aut.); Department of Neurology, University of Mississippi/Jackson, Mississippi/Etats-Unis (8 aut.); Department of Neurology, University of Florida/Gainesville, Florida/Etats-Unis (9 aut.); Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 4; Pp. 426-432; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia of all four limbs, dysarthria, and arreflexia. A variety of measures are currently used to quantify disease progression, including the Friedreich Ataxia Rating Scale, examiner-rated functional disability scales, self-reported activities of daily living and performance measures such as the timed 25-foot walk, 9-hole pegboard test, PATA speech test, and low-contrast letter acuity vision charts. This study examines the rate of disease progression over one and two years in a cohort of 236 Friedreich ataxia patients using these scales and performance measure composites. The Friedreich Ataxia Rating Scale and performance-measure composites captured disease progression, with a greater sensitivity to change over 2 years than over 1 year. The measures differed in their sensitivity to change and in possible bias. These results help to establish norms for progression in FRDA that can be useful in measuring the long-term success of therapeutic agents and defining sample-size calculations for double-blind clinical trials.</EA>
<CC>002B17; 002B17F</CC>
<FD>Hérédodégénérescence spinocérébelleuse de Friedreich; Ataxie; Cytopathie mitochondriale; Pathologie du système nerveux; Essai clinique; Neurologie; Trinucléotide</FD>
<FG>Pathologie de l'encéphale; Maladie dégénérative; Maladie héréditaire; Pathologie de la moelle épinière; Pathologie du système nerveux central; Trouble neurologique; Enzymopathie; Maladie métabolique</FG>
<ED>Friedreich ataxia; Ataxia; Mitochondrial disorder; Nervous system diseases; Clinical trial; Neurology; Trinucleotide</ED>
<EG>Cerebral disorder; Degenerative disease; Genetic disease; Spinal cord disease; Central nervous system disease; Neurological disorder; Enzymopathy; Metabolic diseases</EG>
<SD>Heredodegeneración espinocerebelosa Friedreich; Ataxia; Citopatía mitocondrial; Sistema nervioso patología; Ensayo clínico; Neurología; Trinucleótido</SD>
<LO>INIST-20953.354000181523490050</LO>
<ID>10-0178204</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:10-0178204 |texte= Measuring the Rate of Progression in Friedreich Ataxia: Implications for Clinical Trial Design }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |